Clinical

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

Articles


Researchers suggest that adjusting the prescribing patterns of about 8% of physicians could result in substantial savings.



Medicare Could Save with Use of Generic Cardiovascular Meds

The study found that nearly half of Americans diagnosed with high blood pressure do not have it sufficiently controlled.

 Study Finds Patients with Hypertension Take Drugs that Raise Blood Pressure 

Across all payers, the use of generic statins has resulted in a savings of $11.9 billion annually.

Study: Generic Statins Led to Significant Cost Savings

Besremi is the first interferon approved to treat a disease that causes the overproduction of red blood cells.

FDA Approves Treatment for Rare Blood Disease

If approved, Jardiance would be the first treatment for adults across the full spectrum of heart failure regardless of ejection fraction.

FDA Accepts Supplemental NDA for Jardiance 

Treating and managing patients with paroxysmal nocturnal hemoglobinuria is expensive and requires constant surveillance by the provider and health plan.

Prime Therapeutics Reviews Treatment Costs for Rare Blood Disease

Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group


Study: Financial Incentives Did Not Improve Cholesterol Levels in Those Taking Statins


Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.


Gavreto, Arcalyst Available Through AllianceRx Walgreens Prime

Repatha is now available for children 10 and older to lower low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolemia.

The FDA Approves Repatha for Children with Rare Genetic Disease

Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure.
